These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20005724)

  • 1. Characterization of non-lipid autotaxin inhibitors.
    Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
    Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
    North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
    J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an activity-based probe for autotaxin.
    Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
    Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of boronic acid based inhibitors of autotaxin.
    Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
    J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
    Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
    Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
    Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
    North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
    Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
    Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
    ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.
    Parrill AL; Baker DL
    Expert Opin Ther Pat; 2010 Dec; 20(12):1619-25. PubMed ID: 21047298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood.
    Endo T; Kano K; Motoki R; Hama K; Okudaira S; Ishida M; Ogiso H; Tanaka M; Matsuki N; Taguchi R; Kanai M; Shibasaki M; Arai H; Aoki J
    J Biochem; 2009 Aug; 146(2):283-93. PubMed ID: 19416959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation and biological activities of the autotaxin-LPA axis.
    van Meeteren LA; Moolenaar WH
    Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents.
    Parrill AL; Baker DL
    Anticancer Agents Med Chem; 2008 Dec; 8(8):917-23. PubMed ID: 19075574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
    East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
    van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
    Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
    van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
    J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel point mutations attenuate autotaxin activity.
    Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
    Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
    Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
    Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.